Bellerophon Therapeutics Inc. (NASDAQ:BLPH) saw its shares jump in early trading after the company reported positive results in a mid-stage trial of a treatment for pulmonary hypertension associated with COPD (chronic obstructive pulmonary disease).
The company said the phase 2 trial of its INOpulse inhaled nitric oxide met its primary and secondary goals, showing statistically significant improvement in six-minute walking distance, hemodynamics and blood vessel volume.
In a statement, Dr. Raymond L. Benza of the Cardiovascular Institute at Allegheny General Hospital, Pittsburgh, PA and chairman of Bellerophon's PH-COPD steering committee said: "COPD patients with associated pulmonary hypertension have a poor prognosis with an approximately 4-year life expectancy and high hospitalization rates, which represents a significant unmet medical need for a safe and effective long-term treatment."
The company said it is planning to conduct a larger phase 2b study of the treatment.
In early New York trading, Bellerophon shares were up 8% at US$1.2018 before later in the day, gaining over 5% to $1.19.